Privia Health Group, Inc. (NASDAQ:PRVA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Privia Health Group, Inc. has received a consensus rating of "Moderate Buy" from 14 research firms, with 11 firms assigning a buy rating and one a strong buy rating.
• The average 12-month price target for the stock among analysts is $28.58, with recent target price adjustments ranging from $28.00 to $36.00.
• Despite reporting a revenue increase of 23.4% year-over-year, Privia Health missed earnings expectations, posting an EPS of $0.02 compared to the consensus estimate of $0.05.

Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $28.5833.

Several research analysts recently commented on the stock. JPMorgan Chase & Co. increased their target price on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday, May 28th. Stephens restated an "overweight" rating and set a $32.00 price objective on shares of Privia Health Group in a research note on Thursday, September 4th. Evercore ISI lowered their target price on Privia Health Group from $30.00 to $28.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 9th. Piper Sandler dropped their target price on Privia Health Group from $36.00 to $35.00 and set an "overweight" rating on the stock in a report on Monday, August 11th. Finally, Citigroup restated an "outperform" rating on shares of Privia Health Group in a research note on Friday, August 29th.

Privia Health Group Stock Performance

NASDAQ:PRVA opened at $22.79 on Monday. The stock has a 50-day simple moving average of $21.11 and a 200 day simple moving average of $22.51. Privia Health Group has a 52-week low of $16.47 and a 52-week high of $26.09. The company has a market cap of $2.80 billion, a PE ratio of 207.20, a PEG ratio of 3.30 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). The firm had revenue of $521.15 million during the quarter, compared to the consensus estimate of $466.97 million. Privia Health Group had a net margin of 0.78% and a return on equity of 2.13%. The company's revenue was up 23.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.19 EPS. Privia Health Group has set its FY 2025 guidance at EPS. On average, research analysts predict that Privia Health Group will post 0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Privia Health Group

Institutional investors have recently added to or reduced their stakes in the company. Van Berkom & Associates Inc. bought a new stake in shares of Privia Health Group during the first quarter worth approximately $45,207,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Privia Health Group by 180.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,633,040 shares of the company's stock worth $59,112,000 after purchasing an additional 1,693,870 shares during the last quarter. Nuveen LLC bought a new stake in Privia Health Group in the 1st quarter valued at $26,899,000. Royce & Associates LP bought a new stake in Privia Health Group in the 1st quarter valued at $6,818,000. Finally, Qube Research & Technologies Ltd grew its holdings in Privia Health Group by 93.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 609,278 shares of the company's stock valued at $14,013,000 after buying an additional 294,101 shares in the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.